Study of BI-1206 plus rituximab, with or without acalabrutinib
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests BI-1206 combined with rituximab, and possibly adds acalabrutinib, in people with certain slow-growing B-cell lymphomas that have come back or did not respond to prior treatment. The goal is to see whether this treatment approach shrinks lymphoma safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old when treatment starts.
- Your lymphoma is a B-cell type confirmed by biopsy, such as follicular lymphoma (not grade 3B), mantle cell lymphoma, or marginal zone lymphoma.
- You have measurable swollen lymph nodes or other measurable lymphoma areas.
- Your lymphoma has relapsed, not responded, or there is no standard treatment for it—and you’ve had at least one prior treatment that included rituximab.
- You can have planned tissue/lymph node biopsies, and you’re expected to live at least 12 weeks.
- Your general health is good enough for study treatment (ECOG performance status 0–2), and key blood/organ test results are within allowed limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests a combination of three drugs for people with a slow-growing form of non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see if this new combination can help shrink tumors or slow the disease.
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
Hear when a new Indolent B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.